About this episode
Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration. Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.
Comments
Rate this episode
Episode Details
- Author
- The New York Times
- Show Type
- full
- Audio Format
- audio/mpeg